Positive association between different triglyceride glucose index-related indicators and psoriasis: evidence from NHANES

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 20, 2023

Background Psoriasis is a chronic inflammatory skin disease with effects that extend beyond the skin. Insulin resistance (IR) has been associated psoriasis, but it remains unclear how indicators related to triglyceride glucose (TyG) index, which were associate IR, are condition. Objective The purpose of this study was investigate association between psoriasis and three TyG-related indicators: glucose-body mass index (TyG-BMI), glucose-waist height ratio (TyG-WHtR), circumference (TyG-WC). Methods Data from adults aged 20 80 years in National Health Nutrition Examination Survey (NHANES) 2003 2006 2009 2014 utilized. Institutional Review Board approval documented written consent obtained participants by NHANES (Protocol #2005–06). patients divided into groups based on TyG-BMI, TyG-WC, TyG-WHtR: Q1 (1st quintile), Q2 (2nd-3rd quintiles), Q3 (4th-5th quintiles). Differences further explored. Multivariate logistic regressions used correlation these results expressed as odds ratios (OR) 95% confidence intervals (CI). Subgroup analysis supplementary conducted explore potential influencing factors. Results included 9,291 participants, 260 had psoriasis. Compared TyG-WHtR Q1, there significantly Among indicators, TyG-WC consistently highest OR values Models 1 2 (Model 1: (95% CI) = 2.155 (1.442-3.220); Model 2: 2.029 (1.341-3.069)). While 3, TyG-BMI shows more significant relationship 3 TyG-BMI: 1.948 (1.300-3.000)). Similar observed majority subgroups analysis. Conclusion This identified stable strong positive (TyG-BMI, TyG-WHtR) persisted even after adjusting for multiple It suggested high IR

Language: Английский

---

Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China

British Journal of Dermatology, Journal Year: 2024, Volume and Issue: 191(4), P. 616 - 623

Published: April 18, 2024

Abstract Background Psoriasis and insulin resistance (IR) are closely related, but it remains unclear whether IR affects the treatment of patients with psoriasis. Objective To investigate impairs response to biologic agents in moderate-to-severe plaque Methods This project was based on a prospective cohort study design. Data were collected from Shanghai Effectiveness Evaluation CoHort (SPEECH), which is exploring strategies for psoriasis China. assessed using triglyceride glucose–body mass index (TyG-BMI). severity Area Severity Index (PASI) Physician Global Assessment (PGA). Multiple logistic regression used explore differences between high low levels IR. Subgroup sensitivity analyses performed examine robustness results. Results A total 290 included analysis. Based median TyG-BMI, divided into two groups: The group exhibited higher prevalence diabetes, BMI, fasting blood glucose than group. Further analysis efficacy revealed that had lower PASI 75 [≥ 75% improvement (PASI)], 90 (≥ 90% PASI) PGA 0/1 (‘clear’ or ‘almost clear’) rates after 12 weeks treatment. In group, 81.9% achieved 75, 58.3% 75.7% 0/1. However, proportion responses at each endpoint significantly compared reduced rate more significant indicated by odd ratios. Subsequent subgroup produced consistent Conclusion associated effectiveness biologics

Language: Английский

---

Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3‐year prospective cohort study

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(7), P. 2969 - 2978

Published: April 29, 2024

The response rate to pioglitazone and the predictive factors for its effects on improving liver biochemistry in patients with steatotic disease (SLD) remain elusive, so we aimed investigate these issues.

Language: Английский

---

A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(6), P. 2188 - 2198

Published: Feb. 29, 2024

Abstract Aim To investigate the efficacy and safety of pioglitazone compared to placebo when added metformin plus dapagliflozin, a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM). Materials Methods In multicentre study, randomized, double‐blind, placebo‐controlled design, 249 Korean T2DM suboptimally managed on dapagliflozin were assigned receive either (15 mg daily) or 24 weeks, followed by 24‐week extension. Primary outcomes included changes in glycated haemoglobin (HbA1c), secondary assessing insulin resistance, adiponectin levels, lipid profiles, liver enzymes, body weight waist circumference. Results Pioglitazone administration resulted significant reduction HbA1c levels (from 7.80% ± 0.72% 7.27% 0.82%) 7.79% 0.76% 7.69% 0.86%, corrected mean difference: −0.42% 0.08%; p < 0.01) at weeks. Additional benefits from treatment enhanced sensitivity, increased raised high‐density lipoprotein cholesterol reduced enzyme resulting improvement nonalcoholic fatty disease fat score. Despite no serious adverse events group, therapy was modestly but significantly associated gain Conclusions Adjunctive inadequately controlled demonstrates considerable glycaemic improvement, metabolic benefits, low risk hypoglycaemia. These advantages must be weighed against potential

Language: Английский

---

Stroke in the Patient with Type 2 Diabetes

Endocrine Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Amelioration of metabolic syndrome in high-fat diet-fed mice by total sesquiterpene lactones of chicory via modulation of intestinal flora and bile acid excretion

Food & Function, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Chicory ( Cichorium intybus L.) is a vegetable with medicinal uses and contains many sesquiterpene lactone compounds which could serve as potential candidates for the prevention therapeutic intervention of metabolic syndrome.

Language: Английский

---

Therapeutic Potential and Challenges of Pioglitazone in Cancer Treatment

Applied Sciences, Journal Year: 2025, Volume and Issue: 15(4), P. 1925 - 1925

Published: Feb. 13, 2025

Pioglitazone (ACTOS) is a thiazolidinedione for peroxisome proliferator-activated receptor γ (PPAR-γ) that has been well established the second or third line treatment of type 2 diabetes mellitus. Beyond effects on glucose metabolism, pioglitazone displays positive lipid blood pressure, endothelial function, bone density, and apoptosis cancer cells. In fact, according to in vitro experiments preclinical studies, PPAR-γ ligand currently considered potential target both chemoprevention therapy. ligands are known inhibit cell proliferation metastasis through terminal differentiation underexpression inflammatory mediators. Despite its anticancer properties, was withdrawn by national medicine agencies France Germany, due reports increased incidence bladder cancer. These were associated with European populations undergoing higher doses longer durations treatment. this review, we discuss pharmacokinetics, therapeutic potential, limitations regarding clinical use pioglitazone, focus

Language: Английский

---

Identification of drug combinations to reduce the risk of pioglitazone-related bladder cancer using the FDA adverse event reporting system database

Expert Opinion on Drug Safety, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Emerging studies have uncovered the innovative pharmacological characteristics of pioglitazone (PLZ). However, concerns regarding potential link to an increased risk bladder cancer (BC) had constrained its clinical application. BC reports associated with PLZ and drug combinations containing from 1 January 2004 30 September 2024 were identified Food Drug Administration Adverse Event Reporting System (FAERS) database. odds ratio (ROR) Bayesian confidence propagation neural network (BCPNN) method was applied mine adverse event signals. Of 144 combinations, 15 showed IC025 greater than 3, denoting a strong signal; 44 between 1.5 indicating moderate signal intensity; 36 0 1.5, pointing weak 49 less 0, suggesting no apparent related signal. Importantly, values for all did not surpass value observed when used as monotherapy. Through comprehensive data mining, 14 PTs identified, that specific medication might mitigate PLZ-related BC. Our findings offer valuable insights guiding decisions on combination therapies.

Language: Английский

---

Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment

Cardiovascular Research, Journal Year: 2023, Volume and Issue: 120(1), P. 69 - 81

Published: Dec. 8, 2023

Abstract Aims Duchenne muscular dystrophy (DMD)-associated cardiomyopathy is a serious life-threatening complication, the mechanisms of which have not been fully established, and therefore no effective treatment currently available. The purpose study was to identify new molecular signatures development in DMD. Methods results For modelling DMD-associated cardiomyopathy, we prepared three pairs isogenic control dystrophin-deficient human induced pluripotent stem cell (hiPSC) lines. Two hiPSC lines were obtained by CRISPR/Cas9-mediated deletion DMD exon 50 unaffected cells generated from healthy donor then differentiated into cardiomyocytes (hiPSC-CM). latter subjected global transcriptomic proteomic analyses followed more in-depth investigation selected pathway pharmacological modulation observed defects. Proteomic analysis indicated decrease level mitoNEET protein hiPSC-CM, suggesting alteration iron metabolism. Further experiments demonstrated increased labile pool both cytoplasm mitochondria, ferroportin an increase ferritin transferrin receptor hiPSC-CM. Importantly, correction mutation patient-derived reversed changes metabolism restored normal levels cardiomyocytes. Moreover, hiPSC-CM with deferoxamine (DFO, chelator) or pioglitazone (mitoNEET stabilizing compound) decreased reactive oxygen species Conclusion To our knowledge, this for first time impaired cardiomyocytes, potential reversal effect treatment. This implies that overload-regulating compounds may serve as novel therapeutic agents cardiomyopathy.

Language: Английский

---

Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Versus Uptitrated Metformin in Patients with Type 2 Diabetes without Adequate Glycemic Control: A Randomized Clinical Trial

Diabetes Therapy, Journal Year: 2024, Volume and Issue: 15(11), P. 2351 - 2366

Published: Sept. 16, 2024

We aim to evaluate the efficacy and safety of pioglitazone/metformin fixed-dose combination (FDC) versus uptitrated metformin in patients with type 2 diabetes mellitus (T2DM) without adequate glycemic control.

Language: Английский

---